---
title: Improve walking rhythm and balance
nct_id: NCT06174948
phase: NA
status: RECRUITING
sponsor: Queen Mary University of London
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06174948"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06174948"
last_fetched: "2026-05-10T14:08:11.145Z"
source: "Parkinson's Pathways (curated)"
---
# Improve walking rhythm and balance

**Goal (in five words):** Improve walking rhythm and balance

**Official Title:** The Use of the CUE1/CUE1+ Device in People With Idiopathic Parkinson's Disease and Related Disorders: A Feasibility Study

**Trial ID:** [NCT06174948](https://clinicaltrials.gov/study/NCT06174948)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Queen Mary University of London
- **Target Enrollment:** 70 participants
- **Start Date:** 2024-03-25
- **Completion Date:** 2025-03-31
- **Conditions:** Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, Different Types of Tremor Including Essential Tremor, Dystonia, Multiple System Atrophy, Corticobasal Degeneration, Vascular Parkinsonism, Orthostatic Tremor
- **Interventions:** CUE1 non-invasive device, CUE1+ device active vs sham CUE1+ device
- **Intervention Types:** DEVICE

## Summary For Families

The goal is to test whether a wearable tactile cueing device can be used safely and practically, and whether its vibration cues might help the timing of movement, gait and balance in people with Parkinson's and related movement disorders. Participants wear the non-invasive CUE1 or CUE1+ device, usually on the sternum, which delivers short vibrotactile pulses to provide an external rhythm for steps and posture; the trial compares active versus sham CUE1+ and the device is non-drug so it is used alongside stable Parkinson's medications rather than replacing them. The study is looking for adults 18 and older with idiopathic Parkinson's or related conditions such as PSP, MSA, CBD, vascular parkinsonism, atypical dystonias, various tremor disorders and orthostatic tremor, who can give informed consent and have been on a stable dose of Parkinson's medicines for the past three months. People with cognitive impairment or dementia, severe hearing or visual problems, implanted metal or electronic devices, skin issues where the device would sit, or hypersensitivity to vibrotactile stimulation are excluded.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Adults over 18 years old
* Clinical diagnosis of idiopathic PD and related disorders including progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal degeneration (CBD), and vascular Parkinsonism (VaP) as well as atypical dystonias and tremor disorders and Orthostatic Tremor (OT)
* willing to participate and written consent provided after read the participant information sheet.

Exclusion Criteria:

Individuals with:

* other neurological disorders excluding idiopathic PD, related disorders such PSP, MSA, CBD, and VaP as well as atypical dystonias and tremor disorders, affecting movement, balance and gait
* metabolic or autoimmune disorders affecting movement, balance and gait
* acute orthopaedic disorders influencing balance control and gait
* audiovestibular disorders including severe hearing loss
* visual disturbances, poor eyesight
* not able to provide written consent form to participate
* clinical diagnosis of cognitive impairment including dementia or Alzheimer's.
* Mental impairments (illusions, hallucinations, impulse control disorders) (self-reported)

Technical contraindications related to CUE1 device:

* implanted metallic or electronic devices usage
* hypersensitivity to vibrotactile stimulation
* skin conditions and/or open wound in the area of where the device will be positioned (e.g., sternum) if taking medicines for PD or related disorder, then on stable dose of treatment for the last three months.
```

## Locations (1)

- Queen Mary University of London, London, United Kingdom _(51.5085, -0.1257)_
  - Viktoria Azoidou, PhD — (CONTACT) — v.azoidou@qmul.ac.uk
  - Alastair Noyce, PhD — (CONTACT) — a.noyce@qmul.ac.uk
  - Cristina Simonet, PhD — (PRINCIPAL_INVESTIGATOR)

## Central Contacts

- Cristina Simonet, PhD — (CONTACT) — 020 7882 3543 — c.simonet@qmul.ac.uk
- Viktoria Azoidou, PhD — (CONTACT) — 020 7882 3850 — v.azoidou@qmul.ac.uk

---

*Canonical: https://parkinsonspathways.com/trial/NCT06174948*  
*HTML version: https://parkinsonspathways.com/trial/NCT06174948*  
*Source data: https://clinicaltrials.gov/study/NCT06174948*